Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 1;61(1):55-60.
doi: 10.1097/SHK.0000000000002259. Epub 2023 Oct 20.

SECRETED TRYPTOPHANYL-tRNA SYNTHETASE 1 IS A PROGNOSTIC MARKER IN SEPSIS PATIENTS WITHOUT MONOCYTOPENIA

Kyung Su Kim, Gil Joon Suh, Mirim Jin, Woon Yong Kwon, Yoon Sun Jung, Taegyun Kim, Yoon Tae Kim  1 , Hayoung Kim, Heesu Park
Affiliations

SECRETED TRYPTOPHANYL-tRNA SYNTHETASE 1 IS A PROGNOSTIC MARKER IN SEPSIS PATIENTS WITHOUT MONOCYTOPENIA

Kyung Su Kim et al. Shock. .

Abstract

Objective: This study aimed to test whether the prognostic value of tryptophanyl-tRNA synthetase 1 (WARS1) for 28-day mortality in patients with sepsis was affected by monocytopenia. Methods: A prospective analysis of retrospectively collected samples from 74 sepsis patients was performed. WARS1, C-reactive protein (CRP), and procalcitonin were measured at admission and 24 and 72 h after admission. The prognostic value of WARS1, CRP, and procalcitonin for 28-day mortality was compared using repeated measures analysis of variance and the area under the receiver operating characteristic curve (AUROC). All analyses were performed in patients with or without monocytopenia, defined as an absolute monocyte count less than 0.1 × 10 9 cells/L. Results: WARS1 levels differed significantly between survivors and nonsurvivors when all patients and patients without monocytopenia were assessed ( P = 0.008, P < 0.001, respectively). In contrast, the WARS1 level did not differ between survivors and nonsurvivors with monocytopenia. C-reactive protein and procalcitonin levels were not different between survivors and nonsurvivors regardless of whether they had monocytopenia. The AUROCs of WARS1 at admission and 24 h for mortality were significantly higher in patients without monocytopenia (0.830, 0.818) than in patients with monocytopenia (0.232, 0.196; P < 0.001, both). When patients without monocytopenia were analyzed, the AUROCs of WARS1 for mortality were 0.830 and 0.818 at admission and 24 h, respectively, which were significantly higher than those of CRP (0.586, 0.653) and procalcitonin (0.456, 0.453) at the same time points ( P = 0.024 and 0.034, respectively). Conclusion: WARS1 is a useful biomarker for prognosis in sepsis patients without monocytopenia.

Trial registration: ClinicalTrials.gov NCT01670383.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

References

    1. Jin M. Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications. Exp Mol Med . 2019;51(1):1–10.
    1. Ahn YH, Park S, Choi JJ, et al. Secreted tryptophanyl-tRNA synthetase as a primary defence system against infection. Nat Microbiol . 2016;2:16191.
    1. Choi JS, Yoon BR, Shin JH, et al. Clinical value of full-length tryptophanyl-tRNA synthetase for sepsis detection in critically ill patients—a retrospective clinical assessment. Int J Infect Dis . 2020;97:260–266.
    1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest . 1992;101(6):1644–1655.
    1. Alshari O, Al Zu'bi YO, Al Sharie AH, et al. Evaluating the prognostic role of monocytopenia in chemotherapy-induced febrile neutropenia patients treated with granulocyte colony-stimulating factor. Ther Clin Risk Manag . 2021;17:963–973.

Publication types

Associated data